Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06966362 · ClinicalTrials.gov registry record · Phase 4
Varenicline for Smoking Reduction in Veterans Not Ready To Quit
A Phase 4 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT06966362: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT06966362 is a Phase 4 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 400 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06966362, a Phase 4 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.
Primary Outcome
Participants who report 7-day point-prevalence abstinence from cigarettes at the 6 month follow-up will mailed a saliva collection kit that will test cotinine and anabasine to validate self-reported abstinence from combusted tobacco.
Interventions
- DRUG Motivation-Phase Varenicline
- DRUG Motivation-Phase Nicotine Mini-Lozenge
- DRUG Cessation-Phase Combination Nicotine Replacement Therapy (NRT)
- DRUG Cessation-Phase Varenicline
- BEHAVIORAL Motivation-Phase Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2030-06-28 |
| Phase | Phase 4 |
What is known before NCT06966362 opens enrollment
NCT06966362 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 5 interventions - of which Motivation-Phase Varenicline is the first listed.
NCT06966362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06966362 about?
NCT06966362 is a clinical study titled "Varenicline for Smoking Reduction in Veterans Not Ready To Quit". In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are...
What is the current status of trial NCT06966362?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2026-07-20. Estimated completion is 2030-06-28.
What interventions are being tested in trial NCT06966362?
The interventions under investigation include: Motivation-Phase Varenicline (DRUG), Motivation-Phase Nicotine Mini-Lozenge (DRUG), Cessation-Phase Combination Nicotine Replacement Therapy (NRT) (DRUG), Cessation-Phase Varenicline (DRUG), Motivation-Phase Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT06966362?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06966362's enrollment target sits among peer trials
400 211th of 2000 higher than 1,784 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI